The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pharmas offer gloomy 2009 forecasts

It's that time of year again: Earnings season. Yesterday, all the deal hoopla squeezed out Pfizer and Wyeth's results, but we have them for you today. Plus, get the numbers on Amgen and Bristol-Myers

Cash-hungry biotechs fear Pfizer/Wyeth deal

Pfizer has been sending some clear signals recently that it fully intends to be an aggressive buyer of biotech assets. But its deal yesterday to pay $68 billion in cash and stock for Wyeth is leaving

Pfizer takes $2.3B Bextra charge

News of the Pfizer-Wyeth merger this morning drowned out some not so good news for the company. Just after announcing its $68 billion buyout of Wyeth, Pfizer published its 2008 fourth quarter

Fallout from Pfizer-Wyeth deal begins

When any two mega-companies join hands, some suffering will follow. Who stands to lose when Pfizer and Wyeth wrap up their big merger? There's already one casualty: Dutch biotech Crucell. Wyeth had

Can a $68B Wyeth deal save Pfizer?

It's official: Pfizer has agreed to buy Wyeth in a $68 billion deal. The cash-and-stock transaction will amount to $50.18 per share and will be financed in part by $22.5 billion in debt provided by a

Pfizer nabs Wyeth in $68B deal

Looking for a cure to its financial ailments, Pfizer has opted for a $68 billion dose of Wyeth Pharmaceuticals. The merger of the pharma giants--which was announced bright and early this morning--is

Pfizer in talks to buy Wyeth

To all Pfizer-watchers hoping the company would do something dramatic to change its fortunes: Here you go. Pfizer is negotiating to buy Wyeth in a deal valued at up to $60 billion, the Wall Street

Pfizer in talks to buy Wyeth for $60B

Analysts have been looking for a major buyout from the Pfizer camp, and rumor has it that one is in the works. The Wall Street Journal is reporting that Pfizer has been in talks with Wyeth for months

Can Pfizer weather the coming storms?

Pfizer is riding the same stormy waters as every other drugmaker. But with dual layoff stories last week capping a long season of job cuts and cost-squeezing, industry observers are wondering whether

FDA wants more info on Pfizer's Fablyn

Pfizer has run into a roadblock at the FDA in its longrunning quest to gain an approval for its experimental osteoporosis drug Fablyn. The pharma giant says the FDA has asked for more information on